These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 3045130)

  • 21. Novel genetic immunotoxins and intracellular antibodies for cancer therapy.
    Chen SY; Marasco WA
    Semin Oncol; 1996 Feb; 23(1):148-53. PubMed ID: 8607024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of immunotoxin activity using chemical and biological reagents.
    Wu M
    Br J Cancer; 1997; 75(9):1347-55. PubMed ID: 9155057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
    Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
    J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
    Byers VS; Baldwin RW
    Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells.
    Yu YH; Crews JR; Cooper K; Ramakrishnan S; Houston LL; Leslie DS; George SL; Lidor Y; Boyer CM; Ring DB
    Cancer Res; 1990 Jun; 50(11):3231-8. PubMed ID: 2334918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
    Pimm MV
    Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotoxin: A new tool for cancer therapy.
    Allahyari H; Heidari S; Ghamgosha M; Saffarian P; Amani J
    Tumour Biol; 2017 Feb; 39(2):1010428317692226. PubMed ID: 28218037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant immunotoxins in targeted cancer cell therapy.
    Reiter Y
    Adv Cancer Res; 2001; 81():93-124. PubMed ID: 11430597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of immunotoxin against human glioma cells.
    Manome Y; Watanabe M; Ohno T
    Neurochirurgia (Stuttg); 1989 Sep; 32(5):146-9. PubMed ID: 2797358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of solid tumors with immunotoxins.
    Messmer D; Kipps TJ
    Breast Cancer Res; 2005; 7(5):184-6. PubMed ID: 16168135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Internalization of monoclonal antibodies selected for immunotoxin activity against small-cell lung cancer.
    Weltman JK; Melucci CL; Chen J; Davidson AE
    Hybridoma; 1992 Oct; 11(5):547-59. PubMed ID: 1334041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new immunotoxin built by linking a hemolytic toxin to a monoclonal antibody specific for immature T lymphocytes.
    Avila AD; Mateo de Acosta C; Lage A
    Int J Cancer; 1988 Oct; 42(4):568-71. PubMed ID: 2902018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A gelonin-containing immunotoxin directed against human breast carcinoma.
    Rosenblum MG; Zuckerman JE; Marks JW; Rotbein J; Allen WR
    Mol Biother; 1992 Sep; 4(3):122-9. PubMed ID: 1445665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.
    Webb KS; Poulton SH; Liberman SN; Walther PJ
    J Urol; 1989 Aug; 142(2 Pt 1):425-32. PubMed ID: 2787412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutic strategies to selectively kill cancer cells.
    Panchal RG
    Biochem Pharmacol; 1998 Feb; 55(3):247-52. PubMed ID: 9484789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A carcinoembryonic antigen-directed immunotoxin built by linking a monoclonal antibody to a hemolytic toxin.
    Avila AD; Mateo de Acosta C; Lage A
    Int J Cancer; 1989 May; 43(5):926-9. PubMed ID: 2785509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.
    Shan L; Liu Y; Wang P
    J Basic Clin Med; 2013; 2(2):1-6. PubMed ID: 25309827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.